GSK's Bid To Accelerate Drug Discovery Using AI

By Deirdre Coleman, Contributing Writer

GSK’s goal is to transform drug discovery from a slow, sequential, high-failure process into a rapid, integrated, and patient-focused model with the help of tools like artificial intelligence and data. We spoke to Mark Ramsey, chief data officer for R&D (CDO) at GSK, who leads the development and execution of the data strategy for R&D.

The goal of the data strategy is to allow GSK to execute clinical trials more effectively and efficiently, and to accelerate drug discovery. One example of that is an ongoing project to use previously collected clinical trial data as an alternative to a control arm in a study. That could potentially reduce the cost of clinical trials and provide a better experience for patients.